BIO three-lens brief
Evidence-based stock research on BIO. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved -2.18% yesterday. · Analyst mean target $329.00 — 11% below current (5 analysts).
- Moved -2.18% yesterday.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 8.8pp over 30 days.
- Analyst mean target $329.00 — 11% below current (5 analysts).
BIO closed at $368.75 (-2.18%) as of 2026-09-11. Market cap: $9.87B. P/E (trailing) 45.9. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 8.8pp over 30 days.. Concerns: moved -2.18% yesterday.; analyst mean target $329.00 — 11% below current (5 analysts).. Last quarter: Revenue $651.00M, free cash flow $283.19M.
Why three lenses on BIO, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BIOacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BIO" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BIO brief"></iframe>